Paxlovid Failing, McCullough Protocol More Effective Using Combination of Drugs for COVID-19, FOX

Peter A. McCullough, MD, MPH, internist, cardiologist, epidemiologist and lead author on the McCullough Protocol first published in August 2020 in the American Journal of Medicine appeared on FOX News The Ingraham Angle with coauthor Dr. Harvey Risch from Yale University. McCullough told Laura Ingraham that Pavlovid alone was not sufficient and the CDC slapped a warning on the drug because it prolongs the illness and causes viral rebound. McCullough Protocol includes multiple drugs in a combination resulting in prompt relief of symptoms and no rebound. Note McCullough pronounced the drug "PaxlaVOID" to emphasize the Pfizer drug had a left a void of practical efficacy for sick patients with COVID-19. In 2024, the most recent financial reporting period, Pfizer reported $2.7 billion in Paxlovid sales. This significant revenue increase was driven by a $442 million order from the U.S. government and a general increase in demand due to a recent COVID wave. Paxlovid contributed significantly to Pfizer's overall revenue, which reached $17.7 billion. Courtesy FOX News, The Ingraham Angle, May 26, 2022.

Citations:

McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2021 Jan;134(1):16-22. doi: 10.1016/j.amjmed.2020.07.003. Epub 2020 Aug 7. PMID: 32771461; PMCID: PMC7410805.

McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, Berkowitz RL, Berry AC, Borody TJ, Brewer JH, Brufsky AM, Clarke T, Derwand R, Eck A, Eck J, Eisner RA, Fareed GC, Farella A, Fonseca SNS, Geyer CE Jr, Gonnering RS, Graves KE, Gross KBV, Hazan S, Held KS, Hight HT, Immanuel S, Jacobs MM, Ladapo JA, Lee LH, Littell J, Lozano I, Mangat HS, Marble B, McKinnon JE, Merritt LD, Orient JM, Oskoui R, Pompan DC, Procter BC, Prodromos C, Rajter JC, Rajter JJ, Ram CVS, Rios SS, Risch HA, Robb MJA, Rutherford M, Scholz M, Singleton MM, Tumlin JA, Tyson BM, Urso RG, Victory K, Vliet EL, Wax CM, Wolkoff AG, Wooll V, Zelenko V. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med. 2020 Dec 30;21(4):517-530. doi: 10.31083/j.rcm.2020.04.264. PMID: 33387997.